Alemtuzumab
Title: Alemtuzumab
CAS Registry Number: 216503-57-0
CAS Name: Anti-(human CD52 (antigen)) immunoglobulin G1 (human-rat monoclonal CAMPATH-1H g1-chain) disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer
Additional Names: Campath-1H
Manufacturers' Codes: LDP-03
Trademarks: Campath (Schering AG); MabCampath (Schering AG)
Literature References: Humanized monoclonal antibody directed against the pan-lymphocyte antigen, CD52. Induces complement-mediated cytolysis resulting in lymphocyte depletion. Prepn: L. Riechmann et al., Nature 322, 323 (1988); H. Waldmann et al., WO 8907452 (1989 to Medical Research Council); eidem, US 5846534 (1998 to British Technology Group). Structure-activity study: J. Greenwood et al., Eur. J. Immunol. 23, 1098 (1993). Crystal structure of the antibody combining site: G. M. T. Cheetham et al., J. Mol. Biol. 284, 85 (1998). Clinical evaluation in chronic lymphocytic leukemia: A. Osterborg et al., Br. J. Haematol. 93, 151 (1996); in renal transplant patients: R. Calne et al., Transplantation 68, 1613 (1999). Review: F. J. Dumont, Curr. Opin. Invest. Drugs 2, 139-160 (2001).
Therap-Cat: Antineoplastic; immunosuppressant.
Keywords: Antineoplastic; Monoclonal Antibodies; Immunosuppressant.

Others monographs:
Mukaiyama ReagentPyruvic AcidHydrone®1-Xylylazo-2-naphthol
CapreninIbudilastSodium PeroxidePropargyl Alcohol
SiccaninArylsulfatase BPicrolonic AcidMichler's Ketone
Isanic AcidImidaprilStannous OxalateOlivil
©2016 DrugLead US FDA&EMEA